Search

Insights into respiratory disease through bioinformatics

Here, we review the basic concepts in bioinformatics and genomic data analysis and illustrate the application of these tools to further our understanding of lung diseases

Basophil counts in PBMC populations during childhood acute wheeze/asthma are associated with future exacerbations

Our findings suggest that the proportion of degranulated basophils can also be associated with recurrent exacerbations

Airway Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic Bacteria and Allergy in Childhood Respiratory Disease

To complement early allergic sensitization, monitoring NPM composition may enable early detection and intervention in high-risk children

Atopy-dependent and independent immune responses in the heightened severity of atopics to respiratory viral infections: Rat model studies

The co-exposure responses in the Th2high BN incorporated type I interferon/Th1, alternative macrophage activation/Th2 and Th17 signatures

Anya Jones

Honorary Research Associate

Acute viral bronchiolitis in infants and young children

Anya Deborah Pat Jones Strickland Holt BSc MSc PhD PhD PhD, DSc, FRCPath, FRCPI, FAA Honorary Research Associate Head, Pregnancy and Early Life

Using Systems Biology to understand asthma exacerbations and develop better treatments

Alexander Anthony Deborah Pat Larcombe Kicic Strickland Holt BScEnv (Hons) PhD BSc (Hons) PhD PhD PhD, DSc, FRCPath, FRCPI, FAA Honorary Research

Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort study

Atopy and asthma are commonly initiated during early life, and there is increasing interest in the development of preventive treatments for at-risk children.

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies

Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.